RECRUITING

Endothelial Derived Hyperpolarization Factor and Vascular Control

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Most cardiometabolic diseases are characterized by increased muscle sympathetic nerve activity (MSNA) during rest and exercise which contributes to poor health outcomes. In healthy humans during muscle contraction, there is a blunting of skeletal muscle vascular responsiveness to increases in MSNA. However, the exact mechanisms involved are unknown although, best evidence suggests that the mechanism is endothelium derived, but nitric oxide (NO) and prostaglandin (PG) independent. Endothelium-derived hyperpolarizing factor (EDHF) is a NO and PG independent vasodilator in both cerebral and skeletal muscle circulations, however, it is unknown if EDHF contributes to vascular responsiveness during elevated MSNA. The application of lower body negative pressure (LBNP) is a safe and non-invasive manipulation that can be used to increase MSNA causing vasoconstriction in humans. Therefore, the purpose of this experiment is to determine if acute inhibition of EDHF alters central and peripheral vascular responses to LBNP at rest and during dynamic exercise. Thereby, providing evidence by which EDHF contributes to vascular control in healthy humans and identify it's potential as a therapeutic target for cardiometabolic diseases that are characterized by elevated MSNA

Official Title

Endothelial Derived Hyperpolarization Factor and Regulation of Cerebral and Muscle Blood Flow

Quick Facts

Study Start:2022-02-19
Study Completion:2025-05
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05176379

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 30 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Normotensive (systolic blood pressure \< 130 mmHg and/or diastolic blood pressure \< 85 mmHg) individuals
  2. * Individuals free of cardiovascular disease and metabolic disease
  3. * Individuals free of any form of autonomic dysfunction
  4. * Individuals with a BMI under 30 kg/m²
  5. * Women that are premenopausal with a regular menstrual cycle (26-30 days)
  1. * Smokers, tobacco users (regular use in the last 6 months)
  2. * Individuals with a blood pressure greater than 130/85
  3. * Subjects who use Amiodarone, Sulphaphenazole
  4. * Subjects who use S-warfarin, Tolbutamine, Phenytoin, Lonafarnib
  5. * Cardiometabolic medication use (e.g. anti-hypertensives, insulin-sensitizing, statins)
  6. * Sex hormone replacement medical use (e.g. testosterone, estrogen, progesterone)
  7. * Pregnancy

Contacts and Locations

Study Contact

Jeremy M Kellawan, PhD
CONTACT
4053259028
kellawan@ou.edu

Principal Investigator

Jeremy M Kellawan, PhD
PRINCIPAL_INVESTIGATOR
University of Oklahoma

Study Locations (Sites)

Department of Health and Exercise Science
Norman, Oklahoma, 73019
United States

Collaborators and Investigators

Sponsor: University of Oklahoma

  • Jeremy M Kellawan, PhD, PRINCIPAL_INVESTIGATOR, University of Oklahoma

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-02-19
Study Completion Date2025-05

Study Record Updates

Study Start Date2022-02-19
Study Completion Date2025-05

Terms related to this study

Keywords Provided by Researchers

  • brain blood flow
  • muscle blood flow
  • endothelial function

Additional Relevant MeSH Terms

  • Healthy